These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 36044214)

  • 41. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?
    Hung Y; Chao TF; Liu CJ; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Liao JN; Chung FP; Lin WY; Lin WS; Cheng SM; Chen TJ; Lip GY; Chen SA
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27702803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
    Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
    Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry.
    Patti G; Pecen L; Casalnuovo G; Manu MC; Kirchhof P; De Caterina R
    Clin Res Cardiol; 2023 Nov; 112(11):1517-1528. PubMed ID: 35976428
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Steinberg BA; Shrader P; Kim S; Thomas L; Fonarow GC; Ansell J; Kowey PR; Singer DE; Gersh BJ; Mahaffey KW; Peterson ED; Piccini JP;
    Am Heart J; 2016 Nov; 181():145-152. PubMed ID: 27823686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CHA
    D'Souza M; Carlson N; Fosbøl E; Lamberts M; Smedegaard L; Nielsen D; Torp-Pedersen C; Gislason G; Schou M
    Eur J Prev Cardiol; 2018 Apr; 25(6):651-658. PubMed ID: 29482441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
    Koretsune Y; Yamashita T; Yasaka M; Ono Y; Hirakawa T; Ishida K; Kuroki D; Sumida T; Urushihara H
    J Cardiol; 2019 Mar; 73(3):204-209. PubMed ID: 30477926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial.
    Pokorney SD; Cocoros N; Al-Khalidi HR; Haynes K; Li S; Al-Khatib SM; Corrigan-Curay J; Driscoll MR; Garcia C; Calvert SB; Harkins T; Jin R; Knecht D; Levenson M; Lin ND; Martin D; McCall D; McMahill-Walraven C; Nair V; Parlett L; Petrone A; Temple R; Zhang R; Zhou Y; Platt R; Granger CB
    JAMA Netw Open; 2022 May; 5(5):e2214321. PubMed ID: 35639381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation.
    Yao X; Abraham NS; Alexander GC; Crown W; Montori VM; Sangaralingham LR; Gersh BJ; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908412
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study.
    Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG
    Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials.
    Proietti M; Lip GY
    Am J Med; 2016 Oct; 129(10):1110-6. PubMed ID: 27086494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: AMADEUS Trial.
    Senoo K; Lip GY
    Stroke; 2015 Nov; 46(11):3202-7. PubMed ID: 26463692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Characteristics, Patterns of Use, and incidence of Adverse Events in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants in Colombia.
    Machado-Duque ME; Gaviria-Mendoza A; Reyes JM; Mesa A; Castaño-Gamboa N; Valladales-Restrepo LF; Machado-Alba JE
    Vasc Health Risk Manag; 2023; 19():157-167. PubMed ID: 37008594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study.
    Wetmore JB; Weinhandl ED; Yan H; Reyes JL; Herzog CA; Roetker NS
    Am J Kidney Dis; 2022 Nov; 80(5):569-579.e1. PubMed ID: 35469965
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project.
    Olesen JB; Fauchier L; Lane DA; Taillandier S; Lip GYH
    Chest; 2012 Jan; 141(1):147-153. PubMed ID: 21680645
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.
    Kitazono T; Ikeda T; Ogawa S; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Cavaliere M; Hayashi Y; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Heart Vessels; 2020 Mar; 35(3):399-408. PubMed ID: 31492970
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical outcomes, management, healthcare resource utilization, and cost according to the CHA
    Fan K; Xiao Y; Xue A; Zhou J
    Int J Cardiol; 2024 Dec; 417():132496. PubMed ID: 39214472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
    Wang SV; Franklin JM; Glynn RJ; Schneeweiss S; Eddings W; Gagne JJ
    BMJ; 2016 May; 353():i2607. PubMed ID: 27221664
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.